About this episode

This episode highlights two newly approved antibiotics with significant clinical implications.

In this bonus episode of Medication Talk, join us as we revisit our Notable New Meds of 2025 webinar and highlight two medications that didn’t make it into the main podcast—both newly approved antibiotics with important implications for clinical practice. Listen in as our editors take a deeper look at: Gepotidacin (Blujepa) for uncomplicated urinary tract infectionsAztreonam/avibactam (Emblaveo) for complicated intraabdominal‑abdominal infectionsYou’ll hear practical insights into where these...

Topics covered

• new medications
• antibiotics
• clinical practice
• urinary tract infections
• intraabdominal infections

Keywords

• Gepotidacin
• Blujepa
• Aztreonam/avibactam
• Emblaveo
• antibiotics
• urinary tract infections
• intraabdominal infections

Mentioned in this episode

Products: Gepotidacin, Blujepa, Aztreonam/avibactam, Emblaveo

More episodes of Medication Talk - Expert Insights on Drug Therapy & Patient Care

• GLP-1 Agonists: Clinical Conundrums · April 1, 2026 · 39 min
• Putting Antimicrobial Stewardship Into Practice · March 1, 2026 · 38 min
• Notable New Meds of 2025 · February 1, 2026 · 35 min
• BONUS: Smoking and Vaping Cessation Conversations · January 22, 2026 · 28 min
• Smoking and Vaping Cessation · January 1, 2026 · 37 min
• Considerations with Oral Oncology Meds · December 1, 2025 · 36 min

Explore listener stats, chart rankings, contacts and more on the Medication Talk - Expert Insights on Drug Therapy & Patient Care podcast page.